Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Herszényi, László ^a   Farinati, Fabio ^d   Cardin, Romilda ^d   István, Gábor ^b   Molnár, László D ^c   Hritz, István ^a   De Paoli, Massimo ^d   Plebani, Mario ^d   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN B; CATHEPSIN L; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TUMOR MARKER; UROKINASE; CATHEPSIN; CYSTEINE PROTEINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMOLUMINESCENCE; CLINICAL INDICATOR; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; BLOOD; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL; VILLOUS ADENOMA;

ADENOMA, VILLOUS; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN B; CATHEPSINS; COLORECTAL NEOPLASMS; CYSTEINE ENDOPEPTIDASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 48249109135     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-194     Document Type: Article

References (59)

1. Berger AC Sigurdson ER LeVoyer T Hanlon A Mayer RJ Macdonalds JS Berger AC Catalano PJ Haller DG Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes J Clin Oncol 2005, 23:8706-87012 10.1200/JCO.2005.02.8852 16314630
2. Liang H Wang XN Wang BG Pan Y Liu N Wang DC Hao XS Prognostic factors of young patients with colon cancer after surgery World J Gastroenterol 2006, 12:1458-1462 16552821
3. Palmqvist R Engaras B Lindmark G Hallmans G Tavelin B Nillson O Hammarström S Hafström L Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: A matched case-control study Dis Colon Rectum 2003, 46:1538-1544 10.1007/ s10350-004-6810-z 14605576
4. Northover J Carcinoembryonic antigen and recurrent colorectal cancer Gut 1986, 27:117-122 1433192 3949243 10.1136/gut.27.2.117
5. Carriquiry LA Pineyro A Should carcinoembryonic antigen be used in the management of patients with colorectal cancer Dis Colon Rectum 1999, 42:921-929 10.1007/BF02237104 10411440
6. Duffy MJ Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful Clin Chem 2001, 47:624-630 11274010
7. Magnani JL Steplewski Z Koprowski H Ginsburg V Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin Cancer Res 1983, 43:5489-5492 6193872
8. Chapman MA Buckley D Henson DB Armitage NC Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer Br J Cancer 1998, 78:1346-1349 9823977
9. Morales-Gutierrez V Vegh I Colina F Gomez-Camara A Ignacio Landa J Ballesteros D Carreira PE Enriquez-De-Salamanca R Survival of patients with colorectal carcinoma: Possible prognostic value of tissular carbohydrate antigen 19.9 determination Cancer 1999, 86:1675-1681 10.1002/(SICI)1097-0142(19991101)86:9<1675::AID-CNCR8>3.0.CO;2-9 10547539
10. Reiter W Stieber P Reuter C Nagel D Lau-Warner U Lamerz R Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer Anticancer Res 2000, 20:5195-5198 11326694
11. Stelzner S Hellmich G Koch R Ludwig K Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: A multivariate analysis J Surg Oncol 2005, 15:211-217 10.1002/jso.20196
12. Takahashi Y Mai M Nakazato H Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU Anticancer Res 2005, 25:1377-1384 15865094
13. Safi F Roscher R Bittner R Beger HG The clinical relevance of tumor marker CEA, CA 19-9 in regional chemotherapy for hepatic metastases of colorectal carcinoma Int J Biol Markers 1988, 3:101-106 2977396
14. Louhimo J Carpelan-Holmström M Alfthan H Stenman UH Jarvinen HJ Haglund C Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer Int J Cancer 2002, 101:545-548 10.1002/ ijc.90009 12237895
15. Liotta LA Stetler-Stevenson WG Tumor invasion and metastasis: An imbalance of positive and negative regulation Cancer Res 1991, 51(18 Suppl):5054s-5059s 1884381
16. Premzl A Turk V Kos J Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro J Cell Biochem 2006, 97:1230-1240 10.1002/jcb.20720 16315320
17. Sloane BF Cathepsin B and cystatins: Evidence for a role in cancer progression Semin Cancer Biol 1990, 1:137-152 2103490
18. Murphy G Atkinson S Ward R Garziloric J Reynolds JJ The role of plasminogen activators in the regulation of connective tissue metalloproteinases Ann NY Acad Sci 1992, 667:1-12 10.1111/ j.1749-6632.1992.tb51590.x 1339240
19. Dano K Behrendt N Hoyer-Hansen G Johnson M Lund LR Ploug M Romer J Plasminogen activations and cancer Thromb Haemost 2005, 93:676-681 15841311
20. Krueger S Kalinski T Wolf H Kellner U Roessner A Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture-regulation of cathepsin B expression and invasiveness Cancer Lett 2005, 223:313-322 10.1016/j.canlet.2004.09.050 15896466
21. Cavallo-Medved D Mai J Dosescu J Sameni M Sloane BF Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells J Cell Sci 2005, 118:1493-1503 10.1242/ jcs.02278 15769846
22. Herszenyi L Plebani M Carraro P De Paoli M Di Mario F Kusstatscher S Rugge M Cardin R Naccarato R Farinati F Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer Am J Gastroenterol 1997, 92:843-847 9149198
23. Herszenyi L Hritz I Pregun I Sipos F Juhasz M Molnar B Tulassay Z Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis World J Gastroenterol 2007, 13:676-682 17278189
24. Plebani M Herszenyi L Cardin R Roveroni G Carraro P De Paoli M Rugge M Nitti D Naccarato R Farinati F Cysteine and serine proteases in gastric cancer Cancer 1995, 76:367-375 10.1002/ 1097-0142(19950801)76:3<367::AID-CNCR2820760304>3.0.CO;2-B 8625115
25. Plebani M Herszenyi L Carraro P De Paoli M Roveroni G Cardin R Tulassay Z Naccarato R Farinati F Urokinase-type plasminogen activator receptor in gastric cancer: Tissue expression and prognostic role Clin Exp Metastasis 1997, 15:418-425 10.1023/A:1018454305889 9219730
26. Herszenyi L Plebani M Carraro P De Paoli M Roveroni R Cardin R Tulassay Z Naccarato R Farinati F The role of cysteine and serine proteases in colorectal cancer Cancer 1999, 86:1135-1142 10.1002/ (SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2 10506696
27. Farinati F Herszenyi L Plebani M Carraro P Cardin R De Paoli M Roveroni G Rugge M Nitti D Naccarato R Increased levels of cathepsin B and L, urokinase-type plasminogen activator and inhibitor type-1 as an early event in gastric carcinogenesis Carcinogenesis 1996, 17:2581-2587 10.1093/carcin/17.12.2581 9006092
28. Harbeck N Alt U Berger U Krüger A Thomssen C Janicke F Höfler H Kates RF Schmitt M Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy Clin Cancer Res 2001, 7:2757-2764 11555589
29. Manders P Tjan-Heijnen VC Span PN Grebenchtchikov N Foekens JA Beex LV Sweep FCGJ Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer Cancer Res 2004, 64:659-664 10.1158/0008-5472.CAN-03-1820 14744782
30. Harbeck N Schmitt M Paepke S Allgayer H Kates RE Tumor-associated proteolytic factors UPA and PAI-1: Critical appraisal of their relevance in breast cancer and their integration into decision-support algorithm Crit Rev Clin Lab Sci 2007, 44:179-201 10.1080/10408360601040970 17364692
31. Werle B Kotzsch M Lah TT Kos J Gabrijelcic-Geiger D Spiess E Schirren J Ebert W Fiehn W Luther T Magdolen V Schmitt M Harbeck N Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer Anticancer Res 2004, 24:4147-4161 15736466
32. Offersen BV Pfeiffer P Andreasen P Overgaard J Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in normal-cell lung cancer: Relation to prognosis and angiogenesis Lung Cancer 2007, 43:43-50 10.1016/j.lungcan.2006.11.018
33. Speleman L Kerrebijn JD Look MP Meeuwis CA Fockens JA Berns EM Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma Head Neck 2007, 29:341-350 10.1002/hed.20527 17163465
34. Dorn J Harbeck N Kates R Magdolen V Grass L Soosaipillai A Schalfeldt B Diamandis EP Schmitt M Disease processes may be reflected by correlations among tissue kallikrein proteases but not proteolytic factors UPA and PAI-1 in primary ovarian carcinoma Biol Chem 2006, 387:1121-1128 10.1515/BC.2006.138 16895483
35. Sier CFM Verspaget HW Griffioen G Ganesh S Vloedgraven JH Lamers CB Plasminogen activators in normal tissue and carcinomas of the human esophagus and stomach Gut 1993, 34:80-85 1374105 8432457 10.1136/ gut.34.1.80
36. Iwamoto J Mizokami Y Takahashi K Nakajima K Ohtsubo T Miura S Narasaka T Takeyama H Omata T Shimokobe K Ito M Takehara H Matsuoka T Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer and effects of Helicobacter pylori Scand J Gastroenterol 2005, 40:783-793 10.1080/00365520510015665 16109653
37. Sakakibara T Hibi K Koike M Fujiwara M Kodera Y Ito K Nakao A Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer Cancer Sci 2006, 97:395-399 10.1111/ j.1349-7006.2006.00185.x 16630137
38. Beyer BC Heiss MM Simon EH Gruetzner KU Babic R Jauch KW Schildberg FW Allgayer H Urokinase system expression in gastric carcinoma: Prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens Cancer 2006, 106:1026-1035 10.1002/cncr.21682 16435385
39. Sier CF Vloedgraven HJM Ganesh S Griffioen G Quax PH Verheijen JH Dooijewaard G Welvaart K Velde van de CJ Lamers CB Inactive urokinase and increased levels of its inhibitors type 1 in colorectal cancer liver metastasis Gastroenterology 1994, 107:1449-1456 7926508
40. Ganesh S Sier CF Heerding MM van Krieken JH Griffioen G Welvaart K Velde van de CJ Verheijen JH Lamers CB Verspaget HW Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes's stage B and C colorectal cancer Br J Cancer 1997, 75:1793-1801 9192984
41. Adenis A Huet G Zerimech F Hecquet B Balduyck M Peyrat JP Cathepsin B, L, and D activities in colorectal carcinomas: Relationship with clinical-pathological parameters Cancer Lett 1995, 96:267-275 10.1016/ 0304-3835(95)03930-U 7585467
42. Talieri M Papadopoulou S Scorilas A Xynopoulos D Arnogianaki N Plataniotis G Yotis J Agnanti N Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma Cancer Lett 2004, 205:97-106 10.1016/j.canlet.2003.09.033 15036666
43. Troy AM Sheahan K Mulcahy HE Duffy MJ Hyland JM O'Donoughe DP Expression of cathepsin B and L antigen and activity is associated with early colorectal progression Eur J Cancer 2004, 40:1610-1616 10.1016/ j.ejca.2004.03.011 15196548
44. Kim TD Song KS Li G Choi H Park HD Lim K Hwang BD Yoon WH Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer BMC Cancer 2006, 6:211 16916471 1563482 10.1186/1471-2407-6-211
45. Obermeyer K Krueger S Peters B Falkenberg B Roessner A Röcken C The expression of low density lipoprotein receptor-related protein in colorectal carcinoma Oncol Rep 2007, 17:361-367 17203175
46. Nekarda H Schmitt M Ulm K Wenninger A Vogelsang H Becker K Roder JD Fink U Siewert JR Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer Cancer Res 1994, 54:2900-2907 8187075
47. Ganesh S Sier CFM Heerding MH van Krieken JHJM Griffioen G Welwaart K Velde van de CJ Verheijen JH Lamers CB Verspaget HW Prognostic value of the plasminogen activation system in patients with gastric carcinoma Cancer 1996, 77:1035-1043 10.1002/ (SICI)1097-0142(19960315)77:6<1035::AID-CNCR5>3.0.CO;2-G 8635120
48. Abe J Urano T Konno H Erhan Y Tanaka T Nishino N Takada A Nakamura S Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size Cancer 1999, 86:2602-2611 10.1002/ (SICI)1097-0142(19991215)86:12<2602::AID-CNCR4>3.0.CO;2-S 10594855
49. Yang JL Seetoo DQ Wang Y Ranson M Berney CR Ham JM Russel PJ Crowe PJ Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets Int J Cancer 2000, 89:431-439 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V 11008205
50. Sakakibara T Hibi K Koike M Fujiwara M Kodera Y Ito K Nakao A Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer Br J Cancer 2005, 93:799-803 10.1038/ sj.bjc.6602743 16091756
51. Hirano T Manabe T Takeuchi S Serum cathepsin B levels and urinary excretion of cathepsin B in cancer patients with remote metastasis Cancer Lett 1993, 70:31-44 10.1016/0304-3835(93)90072-H
52. Huber K Kirchheimer C Sedlmayer A Bell C Ermler D Binder BR Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: Comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen Cancer Res 1993, 53:1788-1793 8467497
53. Kos J Nielsen HJ Krasovec M Christensen IJ Cimerman N Stephens RW Brünner N Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer Clin Cancer Res 1998, 4:1511-1516 9626470
54. Nielsen HJ Christensen IJ Sorensen S Moesgaard F Brunner N Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group Ann Surg Oncol 2000, 7:617-623 11005561
55. Sebdzda T Saleh Y Gburek J Warwas M Andrzejak R Siewinski M Rudnicki J Total and lipid-bound plasma sialic acid and diagnostic markers in colorectal cancer patients: Correlation with cathepsin B expression in progression to Dukes stage J Exp Ther Oncol 2006, 5:223-229 16528972
56. Turnbull RB Kyle K Watson FR Spratt J Cancer of the colon: The influence of the no-touch isolation on the survival rates Ann Surg 1967, 166:420-427 1477415 6039601
57. De Bruin PAF Griffioen G Verspaget HW Verheijen JH Lamers CBHW Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps and adenocarcinomas Cancer Res 1987, 47:4654-4657 3621160
58. Duffy MJ van Dalen A Haglund C Hansson L Holinski-Feder E Klapdor R Lamerz R Peltomaki P Sturgeon C Topolcan O Tumor markers in colorectal cancer: European Group on tumour Markers (EGTM) guidelines for clinical use Eur J Cancer 2007, 43:1348-1360 10.1016/j.ejca.2007.03.021 17512720
59. Locker GY Hamilton S Harris J Jessup JM Kemeny N Macdoland JS Somerfield MR Hayes DF Bast RC Jr ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 2006, 24:5313-5327 10.1200/JCO.2006.08.2644 17060676